|
Dec 9
|
Incyte's Late-stage NSCLC Study Meets Primary and Secondary Goals
|
|
Dec 9
|
EXEL or INCY: Which Is the Better Value Stock Right Now?
|
|
Dec 7
|
Incyte Announces Positive Results from Phase 3 Trial Evaluating Retifanlimab (Zynyz®) in Combination with Platinum-Based Chemotherapy in Patients with Non-Small Cell Lung Cancer
|
|
Dec 6
|
Incyte Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
|
|
Oct 30
|
Incyte's Jakafi Demand Is Strong, Analyst Upgrades Stock
|
|
Oct 30
|
Exploring Three High Growth Tech Stocks In The United States
|
|
Oct 30
|
Incyte to Present at Upcoming Investor Conferences
|
|
Oct 30
|
Incyte Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
|
|
Oct 30
|
Incyte Corp (INCY) Q3 2024 Earnings Call Highlights: Strong Revenue Growth and Strategic ...
|
|
Oct 30
|
Q3 2024 Incyte Corp Earnings Call
|
|
Oct 29
|
S&P 500 Gains and Losses Today: Ford Stock Falters as Earnings Miss the Mark
|
|
Oct 29
|
Incyte Breaks Out To 17-Month High As Jakafi Demand Surges
|
|
Oct 29
|
Incyte Rallies on Strong Q3 Revenue, Jakafi Outlook Lifted
|
|
Oct 29
|
Incyte Clocks Mixed Q3 Earnings, But Analyst Sees A Strong Quarter For Jakafi And Opzelura
|
|
Oct 29
|
INCY Q3 Earnings Miss Estimates, Revenues Beat on Higher Product Sales
|
|
Oct 29
|
Here's What Key Metrics Tell Us About Incyte (INCY) Q3 Earnings
|
|
Oct 29
|
Incyte (INCY) Q3 Earnings Miss Estimates
|
|
Oct 29
|
Incyte: Q3 Earnings Snapshot
|
|
Oct 29
|
Incyte Reports 2024 Third Quarter Financial Results and Provides Updates on Key Clinical Programs
|
|
Apr 11
|
Incyte to Report First Quarter Financial Results
|